Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Advanced In Vitro Cell Technologies S.L., a biotech nanomedicine company, engages in the development of drugs through the search for new applications for already-known molecules, and services and reagents. It also develops and markets in vitro cell models with a regulatory and/or predictive value. In addition, the company offers research services; safety assessment of cosmetic raw materials and finished products; vitro services for toxicological evaluation and advising; integrated and customized research for absorption, distribution, metabolism, and elimination; skin biology and cosmetics; anti-tumoural activity of compounds; anti-inflammatory activity of new compounds and cell responses to inflammatory stimuli; biocompatibility for evaluating biocompatible materials; CacoReady system, an integral tool designed to optimize time and costs for intestinal absorption evaluation of compounds; CacoGoblet cell model that combines the absorbent qualities of Caco2 cells with a mucosecreting cell line; TransportPlus, a ready-to-use system for in vitro comparative absorption profiling; AdipoReady kit, an in vitro model for studying the toxicity of metabolites derived from the action of cytochrome P-450 isoenzymes in a ready-to-use system; and liver, lung, and human skin microsomes. Advanced In Vitro Cell Technologies S.L. was founded in 2001 and is based in Barcelona, Spain.

Chemi SpA operates as a chemical pharmaceutical company. It focuses on the development, production and sales of generic active pharmaceutical ingredients, complex to make generics, and peptides. The firm offers pre-filled syringes, vials and oral tablets. The company was founded in 1973 is headquartered in Cinisello Balsamo, Italy.

Kyoto Biken Laboratories, Inc. manufactures veterinary vaccines. It specializes in bovine, porcine, poultry, and plant vaccines. The firm��s business activities include research and development, manufacturing, laboratory diagnosis for field specimens, quality control, after sales validation, and packaging and shipment. The company was founded in June 1948 and is headquartered in Uji, Japan.

Tactical Therapeutics is a clinical-stage company that develops therapeutics for cancer.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

Nippon Zoki Pharmaceutical Co. Ltd. is a private company headquartered in Chuo-ku, Japan, that manufactures pharmaceutical products.

Manufactures and sells pharmaceuticals

PeriCor Therapeutics, Inc. is a private company headquartered in New York, NY, that engages in the developing biologically active therapeutics.

Part of GSK Plc, Beecham Group Plc is a British company located in Middlesex. The firm functions as an investment holding company. It was founded in 1928.\nThe company says this about itself: The principal activity Of the Company is the holding of Intercompany bans and receipt Of interest. The Company had previously been an investment holding company. The Company is a member Of the GlaxoSmithKline Group (the 'Group\"). The directors do not envisage any change to the nature of the business in the future,

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

BASF AB supplies raw materials to paper, chemicals, and construction industries. Its products include construction chemical, crop protection products, dispersions and pigments, plastics, polyurethane systems and coating products. The company was founded in 1953 and is headquartered in Göteborg, Sweden.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Manufactures pharmaceuticals

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.